Form 4: Inovio Pharmaceuticals Director David B. Weiner Reports Stock Transactions

Director David B. Weiner reports the vesting and acquisition of common stock through restricted stock units.

Summary

• David B. Weiner, a director of Inovio Pharmaceuticals, reported transactions involving the company's common stock on February 26, 2024.
• The transactions involved the vesting of restricted stock units (RSUs) and the subsequent acquisition of common stock.
• A total of 2,916 restricted stock units vested, with 972 shares vesting on February 26, 2022, 972 shares vesting on February 26, 2023, and 972 shares vesting on February 26, 2024.
• The vested RSUs were settled in shares of common stock.
• Following these transactions, Weiner directly owns 80,343 shares of Inovio Pharmaceuticals common stock.
• The filing gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey strong positive or negative sentiment.

Positives

• The vesting of restricted stock units and subsequent acquisition of shares by a director could be seen as a positive sign of confidence in the company.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. They are closely watched by investors seeking insights into management's perspective on the company's prospects.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the overall effect is likely minimal.

Key Dates